Quantoom Biosciences
Greater access and autonomy through innovation in bioproduction
We develop open, integrated, affordable and (pre)clinically proven platforms to enable the production of vaccines & therapeutics that scale from development to mass production.
Who We Are
Quantoom Biosciences, a Univercells company, is a biotech embarking on a mission to reinvent bioproduction with open, integrated, affordable and (pre)clinically validated technology platforms.
We are a team of scientists, engineers and clinicians bringing radical innovation to the way we produce vaccines and therapeutics.
Our facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem.
Who We Are
Quantoom Biosciences, a Univercells company, is a biotech embarking on a mission to reinvent bioproduction with open, integrated, affordable and (pre)clinically validated technology platforms.
We are a team of scientists, engineers and clinicians bringing radical innovation to the way we produce vaccines and therapeutics.
Our facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem.
what we do
At Quantoom Biosciences, we are committed to solve some of the biggest production challenges facing vaccines and therapeutics.
We give our partners greater access to drug development and production autonomy through technical and business model innovation.
We do this by providing our partners with technology platforms that include more parts of the value chain in a single solution.
More specifically, we:
- Redesign processes, equipment and consumables for unmatched scalability from lab-scale to commercial production
- Secure logistical and legal access to critical components of a technology’s supply chain
- Clinically-validate our platforms by proving comparability with selected commercial biologics
We are currently evaluating several technologies to produce vaccines & other therapeutics.
what we do
At Quantoom Biosciences, we are committed to solve some of the biggest production challenges facing vaccines and therapeutics.
We give our partners greater access to drug development and production autonomy through technical and business model innovation.
We do this by providing our partners with technology platforms that include more parts of the value chain in a single solution.
More specifically, we:
- Redesign processes, equipment and consumables for unmatched scalability from lab-scale to commercial production
- Secure logistical and legal access to critical components of a technology’s supply chain
- Clinically-validate our platforms by proving comparability with selected commercial biologics
We are currently evaluating several technologies to produce vaccines & other therapeutics.
Our flagship RNA platform
We believe we can solve the challenges of RNA production through disruptive innovation, by delivering greater access and autonomy to this technology.
Despite the rapid uptake of mRNA-based COVID-19 vaccines, the way RNA is synthesized has not significantly advanced since its discovery. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based drugs.
Quantoom’s RNA synthesis platform is changing this : We reduce the barriers to production for research labs, biopharma or CDMOs by lowering the costs and know-how needed to make mRNA.
Using the platform, our partners have the freedom to produce any RNA product without being tied to a specific drug developer or major suppliers thanks to the integration of critical components and ongoing work on licensing rights.
We remove barriers to making mRNA-based vaccines and therapeutics from development up to mass production through an open, integrated and affordable platform for the production of mRNA.
Our flagship RNA platform
We believe we can solve the challenges of RNA production through disruptive innovation, by delivering greater access and autonomy to this technology.
Despite the rapid uptake of mRNA-based COVID-19 vaccines, the way RNA is synthesized has not significantly advanced since its discovery. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based drugs.
Quantoom’s RNA synthesis platform is changing this : We reduce the barriers to production for research labs, biopharma or CDMOs by lowering the costs and know-how needed to make mRNA.
Using the platform, our partners have the freedom to produce any RNA product without being tied to a specific drug developer or major suppliers thanks to the integration of critical components and ongoing work on licensing rights.
We remove barriers to making mRNA-based vaccines and therapeutics from development up to mass production through an open, integrated and affordable platform for the production of mRNA.
What makes us different
We deliver access and autonomy through innovation
- Process intensification and chaining with automated operations in a small footprint system
- Integration of critical components into the supply chain
- Clinically-validation of platforms with (pre-)clinical studies, proving comparability
- Open access, independent licensing of desired drug product
- Secured supply of critical input materials for your operations
- Low set-up and routine cost requirements
- Clinically-validated systems to focus your efforts on drug development
- Eased technology transfer, limited know-how requirements to operate the platforms
- Scalability by design to seamlessly grow from lab to mass production
- Highly flexible platforms fit for a wide range of therapeutic applications
- GMP certified allowing production for clinical studies and commercialization
What makes us different
We deliver access and autonomy through innovation
- Process intensification and chaining with automated operations in a small footprint system
- Integration of critical components into the supply chain
- Validation of platforms with (pre-)clinical studies, proving comparability
- Open access, independent licensing of desired drug product
- Secured supply of critical input materials for your operations
- Low set-up and routine cost requirements
- Clinically-validated systems to focus your efforts on drug development
- Eased technology transfer, limited know-how requirements to operate the platforms
- Scalability by design to seamlessly grow from lab to mass production
- Highly flexible platforms fit for a wide range of therapeutic applications
- GMP certified allowing production for clinical studies and commercialization
Enabling more organisations to explore a wider range of
product development opportunities to get to treatments faster.
Enabling more organisations to explore a wider range of product development opportunities to get to treatments faster.
Our Team
Our team consists of international experts whose talent, experience and commitment
position the company as a key player in therapeutic development and biomanufacturing.
Management Team
José Castillo
Chief Executive Officer
(and Univercells Co-Founder)
Sudhir Sharma
Chief Scientific Officer
Kristof Vandekerckhove
Head of Innovation
Yves Ghislain
Head of Technical Development
Conor Cahill
Head of Product Development
Strategic & Scientific Advisory Board
- Pierre Morgon (board member)
- Jean-Paul Prieels (board member)
- Michel De Wilde
- Andrin Oswald
- Beate Kampmann
